---
title: HIV-HBV Co-Infection and Liver Disease
nct_id: NCT00637429
overall_status: UNKNOWN
sponsor: Bayside Health
study_type: OBSERVATIONAL
primary_condition: HIV Infections
countries: Australia
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00637429.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00637429"
ct_last_update_post_date: 2008-04-02
last_seen_at: "2026-05-12T06:24:28.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# HIV-HBV Co-Infection and Liver Disease

**Official Title:** Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) co-Infection and Liver Disease

**NCT ID:** [NCT00637429](https://clinicaltrials.gov/study/NCT00637429)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 70
- **Lead Sponsor:** Bayside Health
- **Collaborators:** Centre for Clinical Research Excellence in Infectious Diseases, Parkville, Gilead Sciences
- **Conditions:** HIV Infections, HIV-HBV Co-Infection
- **Start Date:** 2007-11
- **CT.gov Last Update:** 2008-04-02

## Brief Summary

Human immunodeficiency virus/Hepatitis B virus (HIV/HBV) co-infections are frequently observed due to shared routes of transmission, with reported figures indicating 6-9% of HIV-infected individuals in developed countries are chronically infected with HBV. HIV infection impacts on the natural progression of HBV infection, increasing levels of HBV replication and the risk of liver-associated mortality. Liver diseases associated with HBV are affected by the antiviral drugs used for HIV infection (toxic side effects), the current immune function in the patient, by improvements in the immune system brought about by control of the HIV infection, and by the development of resistance to the antiviral agents used for both the hepatitis B and the HIV infection. Co-infection with HBV increases the risk for hepatotoxicity in those individuals receiving highly active antiretroviral therapy (HAART) for their HIV infection.

This study will recruit patients who are co-infected with HIV and HBV, and are currently taking or who are about to commence HAART. The study cohort will include HIV-HBV co-infected individuals from the Alfred Hospital, the Royal Melbourne Hospital and high case load GP clinics who are referred to the Alfred Hospital.

The aim of the study is to investigate chronic hepatitis B and its impact on the progression of liver disease in HIV-infected persons receiving HAART.

This will be achieved by 6 monthly assessment with medical history, physical examination, bloods for markers of liver disease and hepatitis B activity and completion of questionnaires to measure adherence and alcohol use.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 18 years of age and older
* HIV positive
* 2 positive Hepatitis B surface antigen results 6 months apart
* provision of informed consent

Exclusion Criteria:

* unable to provide informed consent
```

## Arms

- **General Co-infection** — Individuals with HIV infection and hepatitis B surface antigen positive results who are currently receiving or planning to commence HAART.

## Primary Outcomes

- **To investigate the efficacy and sustainability of HBV-active HAART on hepatitis B suppression by measuring changes in the HBV DNA levels as well as monitoring ALT levels, CD4 counts and HBV serology results.** _(time frame: 6 monthly assessment for 5 years)_

## Secondary Outcomes

- **The surveillance of antiviral resistance mutations that may develop in those individuals who are unable to sustain hepatitis B suppression** _(time frame: 6 monthly assessment for 5 years)_

## Locations (1)

- The Alfred Hospital, Melbourne, Victoria, Australia — _RECRUITING_

## Recent Field Changes (last 30 days)

- `eligibility.sex` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the alfred hospital|melbourne|victoria|australia` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00637429.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00637429*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*